Table 2.
Characteristics | Aprepitant 125/80 mg + standard therapy (n = 146) | Aprepitant 40/25 mg + standard therapy (n = 143) | Standard therapy (n = 150) |
---|---|---|---|
Sex (%) | |||
Female | 24.0 | 25.2 | 25.3 |
Male | 76.0 | 74.8 | 74.7 |
Age (%) | |||
≥65 years | 37.0 | 51.7 | 42.0 |
<65 years | 63.0 | 48.3 | 58.0 |
Mean (SD) | 60.5 (9.7) | 63.3 (9.4) | 62.2 (9.8) |
Use of concurrent emetogenic chemotherapy† (% of patients) | 17.8 | 15.4 | 20.0 |
Cisplatin dose (% of patients) | |||
<70 | 0.0 | 0.0 | 0.0 |
≥70, <80 | 41.8 | 42.0 | 46.7 |
≥80, <90 | 56.2 | 57.3 | 52.7 |
≥90, <100 | 0.0 | 0.0 | 0.0 |
≥100 | 2.1 | 0.7 | 0.7 |
Mean dose (mg/m2) | 76.9 | 76.9 | 76.2 |
Alcoholic drinks/week (at the time of informed consent) (% of patients) | |||
None | 57.5 | 61.5 | 58.0 |
Several times per month | 10.3 | 6.3 | 10.7 |
3–4 times per week | 6.2 | 3.5 | 7.3 |
Almost every day | 26.0 | 28.7 | 24.0 |
History of morning sickness (% of patients) | 43.3 | 38.2 | 44.1 |
History of motion sickness (% of patients) | 9.6 | 4.2 | 11.3 |
History of cisplatin chemotherapy (% of patients) | 17.8 | 15.4 | 17.3 |
History of chemotherapy except cisplatin (% of patients) | 19.9 | 24.5 | 18.7 |
History of CINV except cisplatin chemotherapy (% of patients) | 41.4 | 37.1 | 42.9 |
Primary cancer diagnosis (% of patients)‡ | (n = 150) | (n = 148) | (n = 151) |
Respiratory | 73.3 | 73.0 | 70.2 |
Urogenital | 16.7 | 13.5 | 14.6 |
Digestive | 4.0 | 5.4 | 4.6 |
Eyes/ears/nose/throat | 3.3 | 4.7 | 7.3 |
Other | 3.3 | 3.4 | 3.3 |
†Hesketh level ≥3; analysis population: full analysis set. ‡Analysis population: safety analysis set. SD, standard deviation.